We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Inherited Genetic Variant Increases Risk of Chronic Lymphocytic Leukemia

By LabMedica International staff writers
Posted on 01 Sep 2016
An inherited genetic variant, associated with an increased risk of developing the most common type of leukemia, helps cancer cells survive has been identified and these findings could lead to new ways to target the disease.

Genome wide association studies (GWAS) which analyze genetic information from both patients and healthy individuals to look for genetic associations with diseases have so far identified 31 areas of the genome where DNA variations are linked with an increased risk of developing chronic lymphocytic leukemia (CLL).

Scientists at The Institute of Cancer Research (London, UK) and their colleagues identified for the first time the role that a specific area of the genome plays in the formation of this leukemia. More...
They found that a single letter DNA sequence variation, known as a single nucleotide polymorphism (SNP), at a specific site in the genome disrupts the activity of a protein called Transcription factor p65 or RELA. This protein is involved in a process of controlled cell death that is a key part of the body's natural defense against disease.

The investigators used published GWAS CLL data to scan 517 cases using HumanCNV370-Duo BeadChips (Illumina, San Diego, CA, USA) with Hap1.2M-Duo Custom array data on 2,698 individuals as controls. Others techniques used included epigenetic annotation, plasmid construction and luciferase assays analyzed on a Fluoroskan Ascent FL plate reader (Thermo Fisher Scientific, Waltham, MA, USA), and gene expression and splicing analysis.

The team found that the particular risk SNP, rs539846-A, interferes with the activity switch of a gene, called 'BCL-2 modifying factor' (BMF), that normally works to produce 'pro-death' signals. This makes it harder for RELA to flip on the activity of the gene and reduces the levels of the signal. This loss of 'pro-death' signal tips the balance towards 'pro-survival', so that the CLL cells can sidestep self-destruction. These findings complement work from recent clinical trials that showed drugs that mimic 'pro-death' proteins by targeting the 'pro-survival' BCL-2 pathway can produce a strong anti-cancer effect in CLL patients who had relapsed after initial treatment. The latest discovery could provide important insight into how these and similar drugs work so that their combined use can be optimized.

Richard S. Houlston, MD, PhD, a Professor of Molecular and Population Genetics, and lead investigator said, “Although many significant risk variants for this type of leukemia have been identified, the biological mechanisms through which these variants affect leukemia development have been less well studied. This study highlights the importance of cell death-inducing proteins such as BMF in controlling CLL development and could help in the design of new drugs to treat this disease.” The study was published on August 11, 2016, in the journal Cell Reports.

Related Links:
The Institute of Cancer Research
Illumina
Thermo Fisher Scientific

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.